Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

CDC panel expands RSV vaccine recommendations for at-risk adults aged 50-59, including Pfizer's Abrysvo. Read more here.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV (RSV ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in ...